Data on 1,900 patients with diabetes and multivessel coronary artery disease showed those who underwent coronary artery bypass grafting had lower rates of all-cause mortality, nonfatal myocardial infarction or nonfatal stroke at five years compared with those who had percutaneous coronary intervention with a drug-eluting stent. Lower rates of cardiovascular and cerebrovascular events were also seen in the CABG group, researchers said. The results were presented at the American Heart Association meeting.
CABG boosts outcomes in diabetes plus multivessel CAD
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan